Physician profile
George M Vail
NPI 1760650386
$1,445.52
in general payments reported to CMS, 2019-2025
15 companies · $357 in 2025
The $357 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30.19 · 2020: $41.52 · 2021: $149 · 2022: $201 · 2023: $375 · 2024: $291 · 2025: $357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,008 · Education: $16.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,007.71 |
| Education | $16.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $343.38 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $294.50 | 2020-2025 | Delstrigo, Pifeltro, Zerbaxa |
| Abbvie INC. | $262.20 | 2021-2025 | Mavyret, Teflaro |
| Viiv Healthcare Company | $220.62 | 2021-2025 | Cabenuva, Dovato |
| La Jolla Pharmaceutical Company | $64.40 | 2023-2024 | Xerava, Xacduro |
| Aimmune Therapeutics, INC. | $64.25 | 2024-2025 | Vowst |
| Insmed, INC. | $36.50 | 2024-2025 | Arikayce |
| Theratechnologies INC. | $28.48 | 2020-2021 | |
| Melinta Therapeutics, LLC | $28.40 | 2023 | Kimyrsa, Vabomere, Orbactiv |
| Teleflex LLC | $25.21 | 2025 | Arrow |
| Angiodynamics, INC. | $17.54 | 2021 | |
| Organogenesis INC. | $16.80 | 2019 | |
| Mayne Pharma Commercial LLC | $15.27 | 2020 | |
| Astellas Pharma US INC | $14.58 | 2023 | Cresemba |
| Astrazeneca Pharmaceuticals LP | $13.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Vail listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.